Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.
We tested the hypothesis that gene transfer using recombinant adenovirus vectors (RAds) expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) might offer an alternative therapeutic approach for the treatment of pituitary prolactinomas that do not respond to classical treatment strategies. HSV1-TK converts the prodrug ganciclovir (GCV) to GCV monophosphate, which is in turn further phosphorylated by cellular kinases to GCV triphosphate, which is toxic to proliferating cells. One attractive feature of this system is the bystander effect, whereby untransduced cells are also killed. Our results show that RAd/HSV1-TK in the presence of GCV is nontoxic for the normal anterior pituitary (AP) gland in vitro, but causes cell death in the pituitary tumor cell lines GH3, a PRL/GH-secreting cell line, and AtT20, a corticotrophic cell line. We have used sulpiride- and oestrogen-induced lactotroph hyperplasia within the rat AP gland as an in vivo animal model. Intrapituitary infection of rats bearing oestrogen-induced lactotroph hyperplasia, with RAd/ HSV1-TK and subsequent treatment with GCV, decreases plasma PRL levels and reduces the mass of the pituitary gland. More so, there were no deleterious effects on circulating levels of other AP hormones, suggesting that the treatment was nontoxic to the AP gland in situ. In summary, our results show that suicide gene therapy using the HSV1-TK transgene could be further developed as a useful treatment to complement current therapies for prolactinomas.
Windeatt
S
S
Molecular Medicine and Gene Therapy Unit, School of Medicine, University of Manchester, United Kingdom.
Southgate
T D
TD
Dewey
R A
RA
Bolognani
F
F
Perone
M J
MJ
Larregina
A T
AT
Maleniak
T C
TC
Morris
I D
ID
Goya
R G
RG
Klatzmann
D
D
Löwenstein
P R
PR
Castro
M G
MG
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D002460:Cell Line; D004967:Estrogens / Q000494:pharmacology*; D005455:Fluorescent Antibody Technique; D015316:Genetic Therapy; D018259:Herpesvirus 1, Human / Q000201:enzymology / Q000235:genetics*; D007150:Immunohistochemistry; D008297:Male; D010903:Pituitary Gland, Anterior / Q000821:virology; D010911:Pituitary Neoplasms / Q000628:therapy*; D015175:Prolactinoma / Q000628:therapy*; D051381:Rats; D013937:Thymidine Kinase / Q000235:genetics*; D014407:Tumor Cells, Cultured
D004967:Estrogens; D013937:Thymidine Kinase